about
Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia.IgG subclasses and allotypes: from structure to effector functions.Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3).Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation.Identification of sequence variants influencing immunoglobulin levels.Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases.Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.Affinity of human IgG subclasses to mouse Fc gamma receptors.IgG Glyco-Engineering to Improve IVIg PotencyBroad and potent neutralization of HIV-1 by human-llama fusion antibodies derived from immunized llamasConserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and miceFunctional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell-Mediated Antibody-Dependent Cellular CytotoxicityHuman DC-SIGN and CD23 do not interact with human IgG
P50
Q27322403-D5A8BE09-F634-42C4-825A-3C2AE61FFC51Q33418442-0D7347F1-2662-4F7A-A1D7-AB4AAF3D67A6Q33431066-3162C8DC-2FF2-4759-B08E-2CCA1B26D7ABQ34368678-C48743FB-B375-4578-8B46-5E5A62BD4BD3Q35583369-B663D59B-120B-471B-BBD5-2F469FBA3803Q37461186-AD36D53E-18AA-4A19-8BB7-3FFE65864612Q38752663-BC6C2427-12AD-44CE-999E-3E39240EEE0CQ40077073-BAF1EC0F-F6AD-4035-914B-215DC5D7C5D2Q47700104-41BDCA42-B13E-4AAB-94F6-588E24C03CCCQ48006866-916A1C99-07D1-43FA-A024-F023BE49C289Q52608527-B6F83334-A27E-4FE0-ADB5-6B9315F0175CQ53689028-E0EF575D-7F0E-43D3-846F-6177E8752755Q55116109-5531C5BD-F627-4ADC-B15D-6296F7DAC307Q58572561-63E82F19-99DF-4CC3-9B35-687F6F694195Q59291680-9C4FF505-49BE-4F75-9D24-03E2792C38F4Q89711496-09B7B89A-1EFC-47A3-BF97-7BBB7B60BCCBQ91361128-3B9F398F-42D0-4870-AEF7-02787EDAD6C5Q91776771-2D0B6C68-7A04-4BDF-B4B8-FEFC386CF507
P50
description
researcher ORCID ID = 0000-0002-9127-356X
@en
name
Gillian Dekkers
@ast
Gillian Dekkers
@en
Gillian Dekkers
@es
Gillian Dekkers
@nl
type
label
Gillian Dekkers
@ast
Gillian Dekkers
@en
Gillian Dekkers
@es
Gillian Dekkers
@nl
prefLabel
Gillian Dekkers
@ast
Gillian Dekkers
@en
Gillian Dekkers
@es
Gillian Dekkers
@nl
P31
P496
0000-0002-9127-356X